A methodological framework for drug development in rare diseases

Abstract : Developing orphan drugs is challenging because of their severity and the requisite for effectivedrugs. The small number of patients does not allow conducting adequately powered randomized controlled trials(RCTs). There is a need to develop high quality, ethically investigated, and appropriately authorized medicines,without subjecting patients to unnecessary trials.
Type de document :
Article dans une revue
Orphanet Journal of Rare Diseases, BioMed Central, 2014, 9 (164), pp.1-10. 〈10.1186/s13023-014-0164-y〉
Liste complète des métadonnées

https://hal.inria.fr/hal-01097224
Contributeur : Vitaly Volpert <>
Soumis le : vendredi 19 décembre 2014 - 10:48:12
Dernière modification le : mardi 5 mars 2019 - 10:50:28

Lien texte intégral

Identifiants

Citation

Patrice Nony, Polina Kurbatova, Agathe Bajard, Salma Malik, Charlotte Castellan, et al.. A methodological framework for drug development in rare diseases. Orphanet Journal of Rare Diseases, BioMed Central, 2014, 9 (164), pp.1-10. 〈10.1186/s13023-014-0164-y〉. 〈hal-01097224〉

Partager

Métriques

Consultations de la notice

601